(Q37942997)

25 August 2017

1 reference

title

Pharmacologic interventions for the treatment of opioid dependence and withdrawal (English)

1 reference

25 August 2017

0 references

1 reference

Guthrie SK

1

1 reference

25 August 2017

publication date

1 July 1990

1 reference

DICP : the annals of pharmacotherapy

25 August 2017

published in

1 reference

25 August 2017

volume

24

1 reference

25 August 2017

issue

7-8

1 reference

25 August 2017

page(s)

721-734

1 reference

Clarification and standardization of substance abuse terminology

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Cellular and molecular mechanisms of drug dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Opioid self-administration in rats: pharmacodynamics and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Detoxification after methadone maintenance treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Pharmacological advances in addiction treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Comparison of intravenously administered methadone, morphine and heroin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

The addiction liability of methadon (amidone, dolophine, 10820) and its use in the treatment of the morphine abstinence syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Liability of addiction to 6-dimethylamino-4-4-diphenyl-3-heptanone (methadon, amidone or 10820) in man; experimental addiction to methadon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Methadone maintenance program for AIDS-affected opiate addicts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Methadone treatment and acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Outpatient vs Hospital Methadone Detoxification: An Experimental Comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

The use of serum methadone levels in patients receiving methadone maintenance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Methadone in man: Pharmacokinetic and excretion studies in acute and chronic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Phenytoin-Induced Methadone Withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Methadyl acetate and methadone as maintenance treatments for heroin addicts. A veterans administration cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Effects of clonidine on morphine withdrawal signs in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Clonidine in opiate withdrawal: review and appraisal of clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Clonidine blocks acute opiate-withdrawal symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Noradrenergic hyperactivity in opiate withdrawal supported by clonidine reversal of opiate withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Opiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Efficacy of clonidine in opiate withdrawal: a study of thirty patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Human pharmacology of narcotic antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Mixed agonist-antagonist opiates and physical dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Effects of buprenorphine in heroin addicts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Buprenorphine detoxification from opioid dependence: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Naltrexone treatment of heroin addiction: efficacy and safety in a double-blind dosage comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Opiate Antagonists and the Modification of Heroin Self-Administration Behavior in Man: An Experimental Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Naltrexone treatment of heroin addiction: one-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Narcotic antagonist treatment: clinical experience with naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Heterogeneity of psychiatric diagnosis in treated opiate addicts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Depression and anxiety in heroin addicts: a placebo-controlled study of doxepin in combination with methadone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Methadone Maintenance Dosage Levels and Program Retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

Craving in heroin addicts maintained on the opiate antagonist naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809002400716

10.1177/106002809002400716

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference